Literature DB >> 17251988

Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo.

J Palomeque1, E R Chemaly, P Colosi, J A Wellman, S Zhou, F Del Monte, R J Hajjar.   

Abstract

Recombinant adeno-associated (AAV) viruses have unique properties, which make them ideal vectors for gene transfer targeting the myocardium. Numerous serotypes of AAV have been identified with variable tropisms towards cardiac tissue. In the present study, we investigated the time course of expression of eight different AAV serotypes in rat myocardium and the nature of the immunity against these serotypes. We first assessed whether neutralizing antibodies (NAb) were present for any of the serotype in the rats. We injected 100 microl of each AAV 1-8 serotype (10(12) DNAse resistant particles/ml), encoding LacZ gene, into the apical wall of rat myocardium. At 1, 4, 12 and 24 weeks after gene delivery, the animals were killed and beta-galactosidase (beta-gal) activity was assessed by luminometry. Additionally, LacZ genomic copies and AAV capsids copies were measured through standard polymerase chain reaction analysis and cryo-sections from the area of viral injection were stained for X-gal detection at the same time points. No NAbs were detected against any of AAV serotypes. At all the time points studied, AAV1, 6 and 8 demonstrated the highest efficiency in transducing rat hearts in vivo. Parallel to the results with beta-gal activity, the highest levels LacZ and AAV DNA genomic copies were with AAV1, 6 and 8. The positive X-gal staining depicted by these serotypes confirmed these results. These results indicate that among the various AAV serotypes, AAV1, 6 and 8 have differential tropism for the heart unaffected by pre-existing NAb in the rat. Although AAV 1 and 6 vectors induced rapid and robust expression and reach a plateau at 4 weeks, AAV 8 continued increasing until the end of the study. AAV 2, 5 and 7 vectors were slower to induce expression of the reporter gene, but did reach levels of expression comparable to AAV1 and AAV6 vectors after 3 months.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17251988     DOI: 10.1038/sj.gt.3302895

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  52 in total

Review 1.  Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.

Authors:  Jane T Seto; Julian N Ramos; Lindsey Muir; Jeffrey S Chamberlain; Guy L Odom
Journal:  Curr Gene Ther       Date:  2012-06       Impact factor: 4.391

Review 2.  The potential of adeno-associated viral vectors for gene delivery to muscle tissue.

Authors:  Dan Wang; Li Zhong; M Abu Nahid; Guangping Gao
Journal:  Expert Opin Drug Deliv       Date:  2014-01-03       Impact factor: 6.648

Review 3.  Recombinant adeno-associated virus transduction and integration.

Authors:  Brian R Schultz; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2008-05-20       Impact factor: 11.454

Review 4.  Gene therapy in heart failure.

Authors:  Leif Erik Vinge; Philip W Raake; Walter J Koch
Journal:  Circ Res       Date:  2008-06-20       Impact factor: 17.367

Review 5.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

6.  A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection.

Authors:  Lin Yang; Jiangang Jiang; Lauren M Drouin; Mavis Agbandje-McKenna; Chunlian Chen; Chunping Qiao; Dongqiuye Pu; Xiaoyun Hu; Da-Zhi Wang; Juan Li; Xiao Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

7.  Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines.

Authors:  Lawrence T Bish; Meg M Sleeper; Benjamin Brainard; Stephen Cole; Nicholas Russell; Elanor Withnall; Jason Arndt; Caryn Reynolds; Ellen Davison; Julio Sanmiguel; Di Wu; Guangping Gao; James M Wilson; H L Sweeney
Journal:  Mol Ther       Date:  2008-09-23       Impact factor: 11.454

8.  Adeno-associated virus serotype 9 administered systemically after reperfusion preferentially targets cardiomyocytes in the infarct border zone with pharmacodynamics suitable for the attenuation of left ventricular remodeling.

Authors:  Prasad R Konkalmatt; Feng Wang; Bryan A Piras; Yaqin Xu; Daniel M O'Connor; Ronald J Beyers; Frederick H Epstein; Brian H Annex; John A Hossack; Brent A French
Journal:  J Gene Med       Date:  2012 Sep-Oct       Impact factor: 4.565

Review 9.  Heart failure management: the present and the future.

Authors:  Mohammad N Jameel; Jianyi Zhang
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

Review 10.  Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure.

Authors:  Larissa Lipskaia; Elie R Chemaly; Lahouaria Hadri; Anne-Marie Lompre; Roger J Hajjar
Journal:  Expert Opin Biol Ther       Date:  2010-01       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.